leflunomide has been researched along with Granulomatosis with Polyangiitis in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Granulomatosis with Polyangiitis: A multisystemic disease of a complex genetic background. It is characterized by inflammation of the blood vessels (VASCULITIS) leading to damage in any number of organs. The common features include granulomatous inflammation of the RESPIRATORY TRACT and KIDNEYS. Most patients have measurable autoantibodies (ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES) against MYELOBLASTIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "LEF at a dosage of 30 mg/day appears to be effective in the prevention of major relapses in WG, however, this is associated with an increased frequency of adverse events." | 2.73 | Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. ( de Groot, K; Gross, WL; Hellmich, B; Iking-Konert, C; Manger, K; Metzler, C; Miehle, N; Reinhold-Keller, E, 2007) |
| "Leflunomide treatment was initiated at 20 mg/day and increased to 30 mg/day after 12 weeks and, in patients with partial remission, to 40 mg/day after 24 weeks." | 2.71 | Maintenance of remission with leflunomide in Wegener's granulomatosis. ( Fink, C; Gross, WL; Lamprecht, P; Metzler, C; Reinhold-Keller, E, 2004) |
| "In the past, recommendations for the treatment of Wegener's granulomatosis were primarily based on findings reported from open-label clinical trials." | 2.43 | Advances in the therapy of Wegener's granulomatosis. ( Gross, WL; Hellmich, B; Lamprecht, P, 2006) |
| "Extensive Wegener's granulomatosis (WG) is treated by glucocorticosteroids (GC) and cyclophosphamide (CYC)." | 1.34 | Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. ( Fritz, J; Henes, JC; Horger, M; Kanz, L; Klein, R; Koch, S; Koetter, I; Risler, T, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JJY | 1 |
| Alsaleem, A | 1 |
| Chiang, GPK | 1 |
| Limenis, E | 1 |
| Sontichai, W | 1 |
| Yeung, RSM | 1 |
| Akikusa, J | 1 |
| Laxer, RM | 1 |
| Henes, JC | 2 |
| Kanz, L | 2 |
| Koetter, I | 2 |
| Reinhold-Keller, E | 3 |
| Metzler, C | 2 |
| Fink, C | 1 |
| Lamprecht, P | 2 |
| Gross, WL | 3 |
| Hellmich, B | 2 |
| Jayne, D | 1 |
| Fritz, J | 1 |
| Koch, S | 1 |
| Klein, R | 1 |
| Horger, M | 1 |
| Risler, T | 1 |
| Miehle, N | 1 |
| Manger, K | 1 |
| Iking-Konert, C | 1 |
| de Groot, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica[NCT03576794] | Phase 3 | 94 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for leflunomide and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.
Topics: Adult; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathio | 2019 |
Advances in the therapy of Wegener's granulomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Etan | 2006 |
2 trials available for leflunomide and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Maintenance of remission with leflunomide in Wegener's granulomatosis.
Topics: Adult; Aged; Antirheumatic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Granulomatosi | 2004 |
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
Topics: Administration, Oral; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; C-Reactive Protein; Cyclo | 2007 |
4 other studies available for leflunomide and Granulomatosis with Polyangiitis
| Article | Year |
|---|---|
Rituximab and leflunomide for Wegener's granulomatosis: a long-term follow-up.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Follow-Up Studies; Granulomatosis with | 2011 |
[How long should cyclophosphamide therapy of Wegener's granulomatosis continue?].
Topics: Adjuvants, Immunologic; Administration, Oral; Anti-Infective Agents; Anti-Inflammatory Agents; Anti- | 2002 |
Leflunomide versus methotrexate in Wegener's granulomatosis.
Topics: Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Isoxazoles; Lef | 2007 |
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |